White paper on the current state of ovarian cancer diagnosis and treatment in China in 2023
LI Jin
WEN Hao
LIU Shu-juan
ZOU Dong-ling
LI Jun-dong
WANG Jing
ZHU Jian-qing
SUN Li
WU Xiao-hua
Abstract：Objective To investigate the current clinical diagnosis and treatment status of ovarian cancer in China,identify unmet needs among healthcare professionals and patients,and further standardize the level of ovarian cancer diagnosis and treatment in China.Methods In 2023,a nationwide survey was conducted,involving 571 doctors and 1270 patients from 30 provinces in China.The survey questionnaire primarily covered patient pathology types,treatment modalities,genetic testing,surgical procedures,maintenance therapy,and medication preferences.Results A total of 427 doctors and 1158 patients completed the survey.A comparative analysis between the 2022 and 2023 survey questionnaires revealed that after initial treatment,97％of patients received adjuvant chemotherapy,representing a 4％increase from 2022.Moreover,96％of doctors rec-ommended BRCA1/2 testing to guide treatment,with 75％of patients undergoing BRCA gene testing,marking a 4％increase from 2022.With the increased availability of medications and recognition of their efficacy,there has been a gradual rise in patient's demand for maintenance therapy.The proportion of patients in the surveyed population who were actively undergoing maintenance therapy was 63％,repre-senting a 10％growth from 2022.Among patients not initially advised by doctors to unergo maintenance therapy,52％ex-pressed a willingness to receive this treatment.If BRCA-patients achieved a median progression-free survival(PFS)of 12 months,76％of doctors considered maintenance therapy necessary,and if BRCA-/HRD-patients achieved a median PFS of 9 months,73％of doctors believed maintenance therapy to be essential,indicating that the effectiveness of mainte-nance therapy was gradually gaining recognition among physicians in the treatment of BRCA-patients.Conclusion The findings of this research reflect the current state of ovarian cancer diagnosis and treatment in China.The study primarily focuses on aspects such as BRCA 1/2 genetic testing among ovarian cancer patients,their primary treatment modalities,and physicians'recommendations and patient choices regarding maintenance therapy.These insights provide valuable ref-erences for the standardization of ovarian cancer diagnosis and treatment in China.
Keywords：ovarian cancerdiagnosistreatmentmaintenance therapywhite paper
Publication Date：2023-12-02
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 1225-1232 )